BSA
REGN icon

Braun Stacey Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Braun Stacey Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,516
Closed -$13M – 121
2025
Q1 		$13M Sell
20,516
-976
-5% -$671K 0.53% 71
2024
Q4 		$15.3M Sell
21,492
-654
-3% -$549K 0.57% 71
2024
Q3 		$23.3M Sell
22,146
-1,172
-5% -$1.3M 0.88% 46
2024
Q2 		$24.5M Sell
23,318
-73
-0.3% -$70.8K 0.95% 38
2024
Q1 		$22.5M Buy
23,391
+1,902
+9% +$1.81M 0.89% 49
2023
Q4 		$18.9M Buy
21,489
+465
+2% +$383K 0.84% 53
2023
Q3 		$17.3M Buy
21,024
+35
+0.2% +$27.5K 0.84% 52
2023
Q2 		$15.1M Sell
20,989
-18,223
-46% -$14M 0.7% 69
2023
Q1 		$32.2M Buy
39,212
+19,836
+102% +$15M 0.84% 59
2022
Q4 		$14M Sell
19,376
-161
-0.8% -$119K 0.8% 57
2022
Q3 		$13.5M Buy
19,537
+3,348
+21% +$2.11M 0.82% 56
2022
Q2 		$9.57M Sell
16,189
-5,096
-24% -$3.31M 0.55% 80
2022
Q1 		$14.9M Sell
21,285
-733
-3% -$464K 0.62% 81
2021
Q4 		$13.9M Buy
22,018
+73
+0.3% +$44.9K 0.51% 90
2021
Q3 		$13.3M Buy
+21,945
New +$13.6M 0.53% 89
2017
Q1 		– Sell
-26,597
Closed -$9.76M – 152
2016
Q4 		$9.76M Buy
26,597
+1,214
+5% +$462K 0.64% 80
2016
Q3 		$10.2M Buy
25,383
+2,059
+9% +$826K 0.65% 81
2016
Q2 		$8.15M Sell
23,324
-1,922
-8% -$740K 0.53% 93
2016
Q1 		$9.1M Sell
25,246
-5,967
-19% -$2.46M 0.59% 88
2015
Q4 		$16.9M Buy
31,213
+11,714
+60% +$6.35M 1.06% 39
2015
Q3 		$9.07M Buy
+19,499
New +$10.5M 0.61% 88

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Braun Stacey Associates's REGN Position: Q2 2025 in Review

Braun Stacey Associates sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 20,516 shares — an estimated $13M sold.

Braun Stacey Associates first reported a position in REGN in Q3 2015 and held it in 21 quarters. The position peaked at $32.2M in Q1 2023. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • Braun Stacey Associates reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Braun Stacey Associates sold 20,516 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $13M.
  • Braun Stacey Associates first reported a position in Regeneron Pharmaceuticals in Q3 2015 and held it in 21 quarters.
  • Braun Stacey Associates's Regeneron Pharmaceuticals position peaked at $32.2M in Q1 2023.
  • 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Braun Stacey Associates's 13F filing for Q2 2025, filed 12 Aug 2025.